Illumina cuts annual profit forecast as biotech funding woes linger
/cloudfront-us-east-2.images.arcpublishing.com/reuters/T6BNM4HBWBPB3MOMJ7ZD3LB7BY.jpg)
The offices of gene sequencing company Illumina Inc are shown in San Diego, California January 11, 2016. REUTERS/Mike Blake/File Photo Aug 9 (Reuters) – Illumina Inc (ILMN.O) cut annual profit forecast, in a sign that a funding crunch among its biotech and pharmaceutical clients is expected to weigh on sales for its genetic testing tools … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/3EEQ5YA3AJOULDH3DYJPXDBU3I.jpg)